CN104271744B - 分枝杆菌感染的预防和治疗 - Google Patents

分枝杆菌感染的预防和治疗 Download PDF

Info

Publication number
CN104271744B
CN104271744B CN201280070011.6A CN201280070011A CN104271744B CN 104271744 B CN104271744 B CN 104271744B CN 201280070011 A CN201280070011 A CN 201280070011A CN 104271744 B CN104271744 B CN 104271744B
Authority
CN
China
Prior art keywords
bcg
tuberculosis
vaccine
protein
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280070011.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104271744A (zh
Inventor
詹姆斯·安东尼·特里卡斯
拉谢尔·平托-纳达纳占德兰
瓦威克·约翰·布里顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centenary Institute of Cancer Medicine and Cell Biology
The University of Sydney
Original Assignee
Centenary Institute of Cancer Medicine and Cell Biology
The University of Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centenary Institute of Cancer Medicine and Cell Biology, The University of Sydney filed Critical Centenary Institute of Cancer Medicine and Cell Biology
Publication of CN104271744A publication Critical patent/CN104271744A/zh
Application granted granted Critical
Publication of CN104271744B publication Critical patent/CN104271744B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07004—Sulfate adenylyltransferase (2.7.7.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280070011.6A 2011-12-22 2012-12-20 分枝杆菌感染的预防和治疗 Expired - Fee Related CN104271744B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161579166P 2011-12-22 2011-12-22
US61/579,166 2011-12-22
PCT/AU2012/001569 WO2013091004A1 (en) 2011-12-22 2012-12-20 Prevention and treatment of mycobacterium infection

Publications (2)

Publication Number Publication Date
CN104271744A CN104271744A (zh) 2015-01-07
CN104271744B true CN104271744B (zh) 2017-06-06

Family

ID=48667508

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280070011.6A Expired - Fee Related CN104271744B (zh) 2011-12-22 2012-12-20 分枝杆菌感染的预防和治疗

Country Status (7)

Country Link
US (2) US9610337B2 (enExample)
EP (1) EP2794885B1 (enExample)
CN (1) CN104271744B (enExample)
AU (1) AU2012357637B9 (enExample)
ES (1) ES2655190T3 (enExample)
IN (1) IN2014DN05865A (enExample)
WO (1) WO2013091004A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105567660B (zh) * 2016-01-08 2018-11-20 中国人民解放军第四军医大学 一种大肠杆菌重组表达结核分枝杆菌Rv2837c活性蛋白的方法及其应用
EP3743103A4 (en) * 2018-01-26 2021-03-17 The Regents of The University of California INTRANASAL ADMINISTRATION OF CYCLIC DI-NUCLEOTIDE ADJUVED VACCINE FOR TUBERCULOSIS
CA3098015A1 (en) * 2018-04-26 2019-10-31 Children's National Medical Center Mycobacterial antigen compositions and methods of use
EP3797791A1 (en) * 2019-09-26 2021-03-31 Universidad De Zaragoza Therapeutic efficacy by pulmonary delivery of live attenuated mycobacteria
WO2021243417A1 (en) * 2020-06-05 2021-12-09 Centenary Institute Of Cancer Medicine And Cell Biology Immunogenic formulations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010006607A1 (en) * 2008-07-15 2010-01-21 Satens Serum Institut Vaccines comprising tb10.4

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ309945A (en) * 1995-05-23 2001-04-27 Univ California Abundant extracellular products and their use as vaccines
WO2002004018A2 (en) * 2000-07-10 2002-01-17 Colorado State University Research Foundation Mid-life vaccine and methods for boosting anti-mycobacterial immunity
WO2002086067A2 (en) 2001-04-20 2002-10-31 The Regents Of The University Of California Mycobacterial sulfation pathway proteins and methods of use thereof
US7074559B2 (en) * 2002-03-06 2006-07-11 Refents of the University of Minnesota Mycobacterial diagnostics
EP2355798A1 (en) * 2008-11-12 2011-08-17 Statens Serum Institut Modified cationic liposome adjuvans

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010006607A1 (en) * 2008-07-15 2010-01-21 Satens Serum Institut Vaccines comprising tb10.4

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Rational Design of Multiple TB Antigens TB10.4 and TB10.4-Ag85B as Subunit Vaccine Candidates Against Mycobacterium Tuberculosis.;Shuai Shi et al.;《Pharmaceutical Research》;20091028;第27卷(第2期);第224-234页 *
Targeted induction of antigen expression within dendritic cells modulates antigen-specific immunity afforded by recombinant BCG.;Carlyn U. Kong et al.;《Vaccine》;20110104;第29卷(第7期);第1374–1381页 *
The Regulation of Sulfur Metabolism in Mycobacterium tuberculosis.;Stavroula K. Hatzios et al.;《PLoS Pathogens》;20110721;第7卷(第7期);第e1002036页 *

Also Published As

Publication number Publication date
CN104271744A (zh) 2015-01-07
US9931391B2 (en) 2018-04-03
US9610337B2 (en) 2017-04-04
IN2014DN05865A (enExample) 2015-05-22
AU2012357637B9 (en) 2017-10-19
ES2655190T3 (es) 2018-02-19
EP2794885B1 (en) 2017-10-04
EP2794885A1 (en) 2014-10-29
US20170173137A1 (en) 2017-06-22
EP2794885A4 (en) 2015-07-22
US20160022795A1 (en) 2016-01-28
WO2013091004A1 (en) 2013-06-27
AU2012357637B2 (en) 2017-09-21
AU2012357637A1 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
Baker et al. Burkholderia pseudomallei OMVs derived from infection mimicking conditions elicit similar protection to a live-attenuated vaccine
CN102413837B (zh) 预防再激活的结核病tb疫苗
Sun et al. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis
US8124068B2 (en) Recombinant intracellular pathogen immunogenic compositions and methods of use
JP5713523B2 (ja) エンドソームエスケープ能力増強組み換えｂｃｇ株類
US10010595B2 (en) Live recombinant booster vaccine against tuberculosis
US9931391B2 (en) Prevention and treatment of mycobacterium infection
US11717565B2 (en) Recombinant BCG overexpressing phoP-phoR
CN101801408A (zh) 分枝杆菌的电穿孔和抗原在分枝杆菌中的过量表达
WO2009064825A2 (en) Generation of new bcg vaccine strains protecting against the establishment of latent mycobacterium tuberculosis infection and reactivation from the latent or persistent state
CN102439134B (zh) 包含过表达PhoP和/或PhoP调节子蛋白的重组BCG菌株的结核疫苗
Yi et al. Recombinant M. smegmatis vaccine targeted delivering IL-12/GLS into macrophages can induce specific cellular immunity against M. tuberculosis in BALB/c mice
Yin et al. A promising listeria-vectored vaccine induces Th1-type immune responses and confers protection against tuberculosis
Ko et al. A vaccine targeting lung resident-memory CD4+ T cell phenotype protects against Mycobacterium tuberculosis in mice
JP5994127B2 (ja) 新規な組換えｂｃｇワクチン
Hernandez-Pando et al. Recombinant BCG vaccine candidates
Kondratieva et al. Mycobacterium tuberculosis attenuated by multiple deletions of rpf genes effectively protects mice against TB infection
Romano et al. A Structural View at Vaccine Development Against M. tuberculosis. Cells 2023, 12, 317
Yin et al. Attenuated Listeria monocytogenes, a Mycobacterium tuberculosis ESAT-6 antigen expression and delivery vector for inducing an immune response
Ko et al. A vaccine targeting lung resident-memory CD4 T cell phenotype protects against
JP2022550722A (ja) 弱毒生マイコバクテリアの肺送達による治療有効性
Brodin et al. High Frequency of CD4
Kamanová Bordetella Adenylate Cyclase: Molecular Mechanism of Action and Its Use for Antigen Delivery

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170606

CF01 Termination of patent right due to non-payment of annual fee